Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease

References

• Eknoyan G, Lameire N, Eckardt K-U. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1). Supplement.
   Web of Science ®Google Scholar
• Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. J Am Med Assoc. 2016;316(6):602–610.
   PubMed Web of Science ®Google Scholar
• Doshi SM, Friedman AN. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12:1366–1373.
   PubMed Web of Science ®Google Scholar
• Weir MR. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgrad Med. 2016;128(3):290–298.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes. J Am Coll Cardiol [Internet]. 2018;1–11. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109718353683
   Web of Science ®Google Scholar
• Magee C, Grieve DJ, Watson CJ, et al. Diabetic nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther. 2017;31(5–6):579–592.
   PubMed Web of Science ®Google Scholar
• USRDS ANNUAL DATA REPORT. CKD in the United States chapter 1: CKD in the general population. US Renal Data Syst [Internet]. 2017;1:1–20. Available from: https://www.usrds.org/2016/download/v1_c01_Gen_Pop_16.pdf
   Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology task Fo. J Am Coll Cardiol. 2017;70(14):1785–1822.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes 2018. Diabetes Care. 2018;41(Suppl 1):S1–S159.
   Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med [Internet]. 2015;373(22):2117–2128. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med [Internet]. 2017;377(7):644–657. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet]. 2018 Nov 10 [cited 2018 Nov 10];NEJMoa1812389. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1812389
   Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia [Internet]. 2018 Dec 5 [cited 2018 Nov 9];61(12):2461–2498. Available from: http://link.springer.com/10.1007/s00125-018-4729-5
   PubMed Web of Science ®Google Scholar
• Haynes RB, McKibbon KA, Wilczynski NL, et al. Optimal search strategies for retrieving scientifically strong studies of treatment from medline: analytical survey. Br Med J. 2005;330(7501):1179–1182.
   PubMed Web of Science ®Google Scholar
• Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–473.
   PubMed Web of Science ®Google Scholar
• Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab [Internet]. 2014;16(10):1016–1027. Available from: http://doi.wiley.com/10.1111/dom.12348
   PubMed Web of Science ®Google Scholar
• Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol [Internet]. 2014;2(5):369–384. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2213858713702080
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int [Internet]. 2014;85(4):962–971. Available from: http://dx.doi.org/10.1038/ki.2013.356
   PubMed Web of Science ®Google Scholar
• Fioretto P, Del Prato S, Buse JB, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes Obes Metab [Internet]. 2018;(March 2018):17–20. Available from: http://doi.wiley.com/10.1111/dom.13413
   Google Scholar
• Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1):49–66.
   PubMed Web of Science ®Google Scholar
• Dekkers CCJ, Wheeler DC, Sjöström CD, et al. Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease. Nephrol Dial Transplant [Internet]. 2018;(July):1–7. Available from: http://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfx350/4822429
   PubMed Web of Science ®Google Scholar
• Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia [Internet]. 2016;59(9):1860–1870. Available from: http://link.springer.com/10.1007/s00125-016-4008-2
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol [Internet]. 2017;28(1):368–375. Available from: http://www.jasn.org/lookup/doi/10.1681/ASN.2016030278
   PubMed Web of Science ®Google Scholar
• Wanner C. EMPA-REG OUTCOME : the nephrologist’ s point of view. Am J Cardiol [Internet]. 2018;120(1):S59–67. Available from: http://dx.doi.org/10.1016/j.amjcard.2017.05.012
   Web of Science ®Google Scholar
• Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation [Internet]. 2016;134(10):752–772. Available from: http://circ.ahajournals.org/lookup/doi/10.1161/CIRCULATIONAHA.116.021887
   PubMed Web of Science ®Google Scholar
• Janssen Pharmacuetical. Phase 3 CREDENCE renal outcomes trial of INVOKANA® (canagliflozin) is being stopped early for positive efficacy findings | Janssen [Internet]. [cited 2018 Aug 23]. Available from: https://www.janssen.com/phase-3-credence-renal-outcomes-trial-invokanar-canagliflozin-being-stopped-early-positive-efficacy
   Google Scholar
• Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783–794.
   PubMed Web of Science ®Google Scholar
• Invokana (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, inc; 2017 Jul. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3&type=display
   Google Scholar
• Farxiga (dapagliflozin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017 Oct. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69&type=display
   Google Scholar
• Jardiance (empagliflozin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2017 Dec. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565&type=display
   Google Scholar
• Steglatro (ertugliflozin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2017 Dec. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e6f3e718-bb99-48f1-ab94-b9f0af05fed6&type=display
   Google Scholar
• Pecoits-Filho R, Perkovic V. Are SGLT2 inhibitors ready for prime time for CKD? Clin J Am Soc Nephrol. 2018;13(2):318–320.
   PubMed Web of Science ®Google Scholar
• Wanner C. EMPA-REG Outcome : the nephrologist’s point of view. Am J Med [Internet]. 2017;130(6):S63–72. Available from: http://dx.doi.org/10.1016/j.amjcard.2017.05.012
   PubMed Web of Science ®Google Scholar